

REMARKS

In response to the Restriction Requirement dated March 30, 2009, Applicants elect to pursue claims classified as Group I (claims 1-19). Applicants further elect to pursue (a) viral vectors (claims 2 and 5), (b) adenoviral vector (claim 7), (c) replication deficient viral vector, (d) antibiotic -regulated TAF (claim 120), (e) TSRE from an ARR2PB (claim 13), (f) inducer of apoptosis (claim 16), (g) cytokine (claim 17), and (h) adenoviral vector (claim 18). Applicants withdraw from consideration claims 20-53. Applicants reserve the right to rejoin non-elected subject matter.

The Examiner is invited to contact the undersigned attorney at (512) 536-3167 with any questions, comments or suggestions relating to the referenced patent application.

Respectfully submitted,



Charles P. Landrum
Reg. No. 46,855
Attorney for Applicants

FULBRIGHT & JAWORSKI L.L.P.
600 Congress Avenue, Suite 2400
Austin, Texas 78701
(512) 474-5201

Date: September 30, 2009